Diffusion Pharmaceuticals Achieves Positive Results in Phase I/II Clinical Trial of Trans Sodium Crocetinate in Peripheral Artery Disease

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Diffusion Pharmaceuticals LLC today announced positive results of its Phase I/II proof-of-concept study of Trans Sodium Crocetinate (TSC) in patients suffering from walking impairment due to peripheral artery disease (PAD). The study results, presented orally today to an international audience at the American Heart Association Scientific Sessions, demonstrate that TSC could improve walking ability, delay onset of leg pain and enhance overall quality of life for people with PAD. TSC is a novel small molecule drug that treats hypoxia, the lack of oxygen in tissues that underlies PAD.

Back to news